Friday, Feb. 22, 2019
News Recap:
Time to Change Protocols for Post-SVR Monitoring for Liver Cancer?
In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019)
Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV)
MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario
No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring
Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV.
HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca
Friday, Nov 2, 2018
News Recap:
Report on the Pacific AIDS Network (PAN) 2018 Fall Conference in Kelowna
The Pacific AIDS Network held its annual Fall Conference and AGM October 30-31 in Kelowna. HepCBC attended this year for the first time as a Full Member, due to changes in the PAN Constitution and Bylaws. New Bylaws included: PAN no longer requires its hepatitis C organizational members to offer HIV-related services.
Aging and Viral Hepatitis ...
Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure—but now a study offers hope of early detection, and targets for new treatments. Published in Frontiers in Cell and Developmental Biology, the results show a dramatic increase in expression of sugar-burning 'glycolytic' enzymes in precancerous cirrhotic livers. This increase is associated with a sign
Friday, August 24, 2018
News Recap:
Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...
WASHINGTON -- The FDA on Thursday approved the kinase inhibitor lenvatinib (Lenvima) for the first-line treatment of hepatocellular carcinoma (HCC) patients with unresectable disease.
Approval was based on the REFLECT study, a multicenter non-inferiority trial, which randomized 954 HCC patients 1:1 to either 8 mg or 12 mg oral lenvatinib (depending on the patient's weight) versus 400 mg sorafenib twice daily until disease progression or unacceptable toxic
Friday, April 13, 2018
News Recap:
Canada:
Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...
Friday, April 6, 2018
News Recap:
HCV – Liver Cancer (HCC):
Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C. Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018. It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation.
Testing for he...
PARIS — Liver cancer, one of the greatest challenges to hepatologists today, will be in the spotlight at the upcoming International Liver Congress (ILC) 2018.
It will become an even greater challenge in the near future, said Morris Sherman, PhD, from the University of Toronto, who is chair of the Canadian Liver Foundation.
"Liver cancer is increasing in most Western countries, partly because of the hepatitis C epidemic that occurred in the 1950s and 19
MedicalResearch.com Interview with: Sang Min Park MD, MPH, PhD: Chief, Department of Family Medicine, Seoul National University College of Medicine; Director, Health Promotion Center, Seoul National University Hospital; Professor, Department of Biomedical Science & Family Medicine Seoul National University College of Medicine, Seoul, Korea
What is the background for this study? What are the main findings?
Response: Chronic hepatitis B patients hav
